Secondary Logo

Speaker Schedule

JAIDS Journal of Acquired Immune Deficiency Syndromes: January 2016 - Volume 71 - Issue - p 16–33
doi: 10.1097/01.qai.0000479573.84388.81
Abstract
Free
Back to Top | Article Outline

Sunday, September 27, 2015

Coffee and Gathering 2:00–2:30 PM Harborside Foyer

Back to Top | Article Outline

Session A

Comorbidities and Hepatitis C

Harborside Ballroom D&E

Chairpersons and Discussants:

Robert R. Redfield, MD, Institute of Human Virology University of Maryland School of Medicine

John Bartlett, Johns Hopkins University

Alexey Mazus, MD, Moscow Center for HIV/AIDS Prevention and Treatment

Franco Buonaguro, MD, National Cancer Institute “Fondazione Pascale”

2:30 Shyam Kottilil, MD, PhD, Institute of Human Virology University of Maryland School of Medicine

Introduction to Hepatitis C Mini-Symposium A-101

2:40 Kristen Marks, MD, Weill Cornell Medical College

HCV treatment as prevention A-102

3:00 Camilla Graham, MD, Harvard Medical School

Price, Cost-Effectiveness and Affordability of Hepatitis C Drugs: How Did We Get Into This Mess? A-103

3:20 Kenneth Sherman, MD, University of Cincinnati

Comorbidities and Hepatitis C A-104

3:40 Barry Peters, MD, Kings College London

The metabolic and cardiovascular complications of HIV A-105

4:00 John Bartlett, MD, Johns Hopkins University School of Medicine

HIV Infection: What's New Novel and Exciting A-106

4:20 Alexey Mazus, MD, Head of Moscow Center for HIV/AIDS Prevention and Treatment

HIV/HCV coinfection: modern treatment strategies, problems in Eastern Europe A-107

4:40 Franco Buonaguro, MD, National Cancer Institute “Fondazione Pascale”

Viral and cellular biomarkers in HPV-related cancers A-108

5:00 Joel Palefsky, MD, University of California, San Francisco

Pathogenesis of anal cancer A-109

5:20 Corey Casper MD, MPH, Fred Hutchinson Cancer Research Center

Translational Research to Advance the Prevention and Treatment of HIV-Associated Malignancies A-110

5:40 Richard Chaisson, MD, Johns Hopkins Center for Tuberculosis Research and Center for AIDS Research

Controlling the Impact of HIV-related Tuberculosis A-111

6:00 Tracy Sparkes, PharmD, University of Maryland School of Pharmacy

Impact of Antiretroviral Regimen on Renal Transplant Outcomes in HIV-Infected Recipients A-112

Opening Reception (Harborside Foyer) and Poster Session (Kent A, B & C) 6:30–8:15 PM

Back to Top | Article Outline

Monday, September 28, 2015

Session B

Status of HIV Cure Research

Harborside Ballroom D&E

Chairpersons and Discussants:

George Shaw, MD, PhD, University of Pennsylvania

Anders Vahlne, MD, PhD, Karolinska Institutet

8:20 Robert Siliciano, MD, PhD, Johns Hopkins University

Unique features of effector to memory transition render CD4+ T cells permissive for latent HIV infection B-101

8:40 Guido Poli, MD, Vita-Salute San Raffaele University

Towards Achieving a State of Reversible HIV-1 Latency in Primary Monocyte-Derived Macrophages (MDM) by M1 Polarization B-102

9:00 Keith Jerome, MD, PhD, University of Washington Lab Medicine

Genome-directed antiviral endonuclease therapy: promise and perils B-103

9:20 David Margolis, MD, University of North Carolina at Chapel Hill

HIV Cure Research: a status report B-104

9:40 John Frater, MD, PhD, University of Oxford

Post Treatment Control: what predicts long-term HIV remission? B-105

10:00 Julie Overbaugh, PhD, Fred Hutchinson Cancer Research Center

Characterizing the basis for the broad and potent HIV-specific neutralizing antibody response of infants B-106

10:20 Jonathan Karn, PhD, Case Western Reserve University

Distinct mechanisms of hormonal control of HIV latency in T-cells and microglial cells B-107

Coffee Break 10:40–11:00 AM Harborside Foyer

11:00 Stephen H. Hughes, PhD, National Cancer Institute

Specific HIV integration sites are linked to clonal expansion and persistence of infected cells B-108

11:20 Deborah Persaud, MD, Johns Hopkins Children's Center

HIV Latency and Perinatal Infection B-109

11:40 Fabio Romerio, PhD, Institute of Human Virology University of Maryland School of Medicine

The HIV-1 antisense transcript AST promotes latency by recruiting PRC2 to the 5'LTR B-110

12:00 Paolo Lusso, MD, PhD, National Institute of Allergy and Infectious Diseases

Sulfotyrosine-Mediated V2-V3 Interaction Stabilizes the HIV-1 Envelope Trimer Facilitating Immune Evasion B-111

12:20–2:00 PM Lunch

Back to Top | Article Outline

Session C

Molecular Epidemiology: Viruses and Cancer

Harborside Ballroom D&E

Chairpersons and Discussants:

Stanley Weiss, MD, FACP, FACE, Rutgers New Jersey Medical School

Douglas Blayney, MD, Stanford Cancer Center

Alash'le Abimiku, PhD, Institute of Human Virology University of Maryland School of Medicine

Warren Johnson, MD, Weill Cornell Medical College

James Goedert, MD, National Cancer Institute

2:00 Mark K. Slifka, PhD, Oregon National Primate Research Center at Oregon Health & Science University

Vaccines and Mechanisms of Host Defense C-101

2:20 Beatrice Hahn, MD, Perelman School of Medicine, University of Pennsylvania

Dissecting HIV-1 Transmission: Understanding Transmitted Founder Virus Biology C-102

2:40 Man Charurat, PhD, Institute of Human Virology University of Maryland School of Medicine

Genetic Diversity of HIV Reveals the Epidemiological Role of High Risk Groups in Nigeria C-103

3:00 Esther H. Chang, PhD, Georgetown University

A Tumor-Targeting Delivery Platform for p53 Therapy: Translation and Clinical Applications C-104

3:20 Gloria Yuen Fun Ho, PhD, Albert Einstein College of Medicine

Insulin and IGFBP-3 Associated with Lung Cancer Susceptibility in Current Smokers C-105

3:40 Myron Essex, DVM, PhD, T.H. Chan School of Public Health, Harvard University

The Botswana Combination Prevention Project (BCPP): Addressing the UN 90-90-90 Targets C-106

Coffee Break 4:00–4:20 PM Harborside Foyer

4:20 Sten Vermund, MD, PhD, Institute for Global Health, Vanderbilt University Medical Center

Stigma and Depression Among Newly Diagnosed HIV Infected MSM in China C-107

4:40 Howard Strickler, MD, Albert Einstein College of Medicine

Recent Cohort Data Suggest Revising US Cervical Cancer Screening Practices in HIV+ Women C-108

5:00 Clement Adebamowo, BM, ChB, ScD, FWACS, FACS, Institute of Human Virology University of Maryland School of Medicine

HPV Associated Cervical Cancer in HIV negative African Women C-109

5:20 Edward L. Murphy Jr, MD, MPH, University of California, San Francisco

Human T lymphotropic virus types 1 and 2 (HTLV-1 and -2) and hepatitis C virus (HCV) epidemiology: lessons from studies of blood donors C-110

5:40 John Vertefeuille, PhD, Centers for Disease Control and Prevention

Progress toward poliomyelitis eradication—Nigeria, January 2014–July 2015 C-111

Back to Top | Article Outline

Tuesday, September 29, 2015

Session D

HIV Structural Biology, Immunology and Vaccines

Harborside Ballroom D&E

Chairpersons and Discussants:

Robert C. Gallo, MD, Director, Institute of Human Virology University of Maryland School of Medicine

Georgia Tomaras, PhD, Duke Human Vaccine Institute

José Esparza MD, PhD, Adjunct Professor, Institute of Human Virology University of Maryland School of Medicine

Nina Russell, MD, Bill and Melinda Gates Foundation

Thomas Lehner, CBE, MD, Kings College London

8:20 Rogier Sanders, PhD, Weill Cornell Medical College

HIV-1 neutralizing antibodies induced by native-like envelope trimers D-101

8:40 Kwinten Sliepen MSc, University of Amsterdam

Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity D-102

9:00 John Moore, PhD, Weill Cornell Medical College

Studies on native-like SOSIP.664 trimers and other forms of Env D-103

9:20 Heather Desaire, PhD, University of Kansas

Molecular-level analysis of Env: What's on native trimers and how can we reproduce it in a vaccine? D-104

9:40 Theresa L. Chang PhD, Rutgers University

Integrin a4b7 expression increases HIV susceptibility in activated cervical CD4+ T cells via an HIV attachment-in dependent mechanism D-105

10:00 Douglas Nixon, MD, PhD, George Washington University

Cellular Immune correlates Analysis of an HIV-1 Pre-exposure Prophylaxis Trial D-106

10:20 Antje Heit, MD, PhD, Fred Hutchinson Cancer Research Center

Vaccination establishes CXCR5+PD1+CD4+ peripheral blood germinal center T follicular helper cell relatives in humans D-107

Coffee Break 10:40–10:55Harborside Foyer

10:55 Michel Nussenzweig, MD, PhD, The Rockefeller University

Special Lecture: Human Antibodies to HIV-1 D-108

11:20 Jeffrey Ravetch, MD, PhD, The Rockefeller University

Special Lecture: Fc Effector functions in the anti-viral response D-109

11:45 AM–1:00 PM Lunch

Back to Top | Article Outline

Session E

Global Virus Threats: Translation of Basic Science to Public Health Practice

Harborside Ballroom D&E

Chairpersons and Discussants:

Carl Dieffenbach, PhD, Division of AIDS, National Institute of Allergy and Infectious Diseases

Prof. Bernhard Fleckenstein, Universitätsklinikum Erlangen

Susan Buchbinder, MD, University of California, San Francisco

John Idoko, MD, National Agency for the Control of AIDS, Abuja, Nigeria

1:00 Robert C. Gallo, MD, Director, Institute of Human Virology University of Maryland School of Medicine

Introduction to Reinhard Kurth Memorial Lecture

1:05 Harald zur Hausen, MD, Nobel Laureate, German Cancer Research Center in the Helmholtz Association

Reinhard Kurth Memorial Lecture: Zoonotic Origin of Some Common Human Cancers and Multiple Sclerosis? E-101

1:50 Robert C. Gallo, MD, Director, Institute of Human Virology University of Maryland School of Medicine

Introduction to Lifetime Achievement Awards

1:55 Anthony Fauci, MD, National Institute of Allergy and Infectious Diseases

Ending the HIV/AIDS Pandemic: The Convergence of Treatment and Prevention E-102

2:40 Barton Haynes, MD, Duke Human Vaccine Institute

The Pathway to HIV Vaccine Development E-103

3:10 Larry Corey, MD, Fred Hutchinson Cancer Research Center

Can non neutralizing antibodies be the basis for an effective HIV vaccine? Can we determine if RV 144 is “real or Memorex”? E-104

Coffee Break 3:40–4:10 PM Harborside Foyer

4:10 Erica Ollmann Saphire, PhD, The Scripps Research Institute

Antibodies Against Ebola Virus: Results of the Viral Hemorrhagic Fever Immunotherapeutic Consortium E-105

4:40 Cliff Lane, MD, National Institute of Allergy and Infectious Diseases

Establishment of a Clinical Research Program in the Setting of the Ebola Outbreak in West Africa E-106

5:10 Salim Abdool Karim, PhD, Director, Centre for the AIDS Programme of Research in South Africa (CAPRISA)

Advancing Global Health: Lessons from the response to the HIV epidemic E-107

6:15 PMGala Reception—Harborside Foyer

7:00 PMLifetime Achievement Awards Dinner—Harborside Ballroom C

Back to Top | Article Outline

Wednesday, September 30, 2015

Session F

Pathogenesis Research: Viruses, Cancer and Host Factors

Harborside Ballroom D&E

Chairpersons and Discussants:

Anders Vahlne, MD, PhD, Karolinska Institutet

Eduardo Sotomayor, MD, George Washington University School of Medicine & Health Sciences

Kevin Cullen, MD, Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine

8:30 Mario Stevenson, PhD, University of Miami

Pharmacologic inhibition of the HIV-1 vif:apobec axis F-101

8:50 Alfredo Garzino-Demo, PhD, Institute of Human Virology

HIV-1 matrix protein p17 promotes lymphangiogenesis by autophagy-mediated unconventional proteins secretion F-102

9:10 Wuyuan Lu, PhD, Institute of Human Virology

A conformational switch that turns on the B cell growth-promoting activity of the HIV-1 matrix protein p17 F-103

9:30 Luigi Buonaguro, MD, National Cancer Institute, “Fondazione Pascale”

Hepatitis virus associated liver cancer: pathogenesis and immunotherapeutic strategies F-104

9:50 Isaac Witz, MD, PhD, Tel Aviv University

Site-Specific Metastasis Revisited F-105

10:10 Anthony DeVico PhD, Institute of Human Virology

Transition State Gp120 Structures as HIV Vaccines F-106

Coffee Break 10:30–10:50 AM Harborside Foyer

10:50 Genoveffa Franchini, National Cancer Institute, Bethesda

Adjuvant dependant RAS activation and mucosal envelope antibody to V2 correlate with reduced risk of Sivmac251 acquisition F-107

11:10 Thomas Lehner, CBE, MD, Kings College London

The role of a dual pre- and post- entry innate and adaptive immune mechanism in protection against HIV-1 infection F-108

11:30 Krishanu Ray, PhD, University of Maryland School of Medicine

Antigenicity of the Human Immunodeficiency Virus Envelope on Virions in Solution by Fluorescence Correlation Spectroscopy F-109

11:45 AM–12:45 PM Lunch

Back to Top | Article Outline

Session G

Immunology and Inflammation

Harborside Ballroom D&E

Chairpersons and Discussants:

Luigi Buonaguro, MD, National Cancer Institute, “Fondazione Pascale”

William Hall, PhD, University College Dublin

George Pavlakis, MD, PhD, National Cancer Institute

Leonid Margolis, PhD, National Institute of Child Health and Human Development

12:45 Ellis L. Reinherz, MD, Dana-Farber Cancer Institute

Special Lecture: The T cell receptor is a mechanosensor G-101

1:15 Andrés Finzi, PhD, University of Montreal

Modulating Env conformation: a new approach to eliminate HIV-1-infected cells G-102

1:35 Richard Koup, MD, Vaccine Research Center, National Institute of Allergy and Infectious Diseases

Use of bnAbs and bnAb-based bispecific antibodies to target HIV-expressing cells in vivo G-103

1:55 Margaret Ackerman, PhD, Thayer School of Engineering at Dartmouth College

Breaking the species barrier: IgG subclasses in man and macaques G-104

2:15 Galit Alter, PhD, Harvard Medical School, Ragon Institute of MGH, MIT and Harvard

Defining protective antibody profiles against HIV utilizing systems serology G-105

2:35 Falk Nimmerjahn, PhD, Lehrstuhl Genetik, Friedrich-Alexander Universität Erlangen-Nürnberg

The pro- and anti-inflammatory effector functions of IgG G-106

2:55 Eric Sundberg, PhD, Institute of Human Virology

Enzymatic manipulation of antibody Fc-mediated effector functions G-107

Coffee Break 3:15–3:40 PM Harborside Foyer

3:40 Leonid Margolis, MD, National Institute of Child Health and Development

Some HIV-1 virions are more equal than others: Mosaics of Envs on individual HIV virions as evaluated with flow virometry G-108

3:55 Hua Cheng, PhD, Institute of Human Virology

TBK1/IKKε, the non-canonical IκB kinases, promote survival and proliferation of HTLV-1-transformed T cells by maintaining Stat3 activity G-109

4:10 Ira Berkower MD, PhD, Lab of Immunoregulation, FDA

Live attenuated rubella vectors stably express SIV Gag and HIV Env proteins in a highly immunogenic vaccine platform G-110

4:25 Kenneth Bagley, PhD, Profectus Biosciences

DNA prime/subunit boost using SIVE660 based rhFLSC yields 75% efficacy against cross clade SIVmac251 intrarectal challenge G-111

4:40 Closing Remarks from Dr. Gallo—Meeting Adjourns 4:55 PM

Introduction to Hepatitis C Mini-Symposium A-101

Shyam Kottilil, MD, PhD, Institute of Human Virology

HCV treatment as prevention A-102

Kristen Marks, MD, Weill Cornell Medical College

Price, Cost-Effectiveness and Affordability of Hepatitis C Drugs: How Did We Get Into This Mess? A-103

Camilla Graham, MD, Harvard Medical School

Comorbidities and Hepatitis C A-104

Kenneth Sherman, MD, University of Cincinnati

The metabolic and cardiovascular complications of HIV A-105

Barry Peters, MD, Kings College London

HIV Infection: What's New Novel and Exciting A-106

John Bartlett, MD, Johns Hopkins University School of Medicine

HIV/HCV coinfection: modern treatment strategies, problems in Eastern Europe A-107

Mazus, MD, Head of Moscow Center for HIV/AIDS Prevention and Treatment

Viral and cellular biomarkers in HPV-related cancers A-108

Franco Buonaguro, MD, National Cancer Institute “Fondazione Pascale”

Pathogenesis of anal cancer Joel A-109

Palefsky, MD, University of California, San Francisco

Translational Research to Advance the Prevention and Treatment of HIV-Associated Malignancies A-110

Corey Casper MD, MPH, Fred Hutchinson Cancer Research Center

Controlling the Impact of HIV-related Tuberculosis A-111

Richard Chaisson, MD, Johns Hopkins Center for Tuberculosis Research and Center for AIDS Research

Impact of Antiretroviral Regimen on Renal Transplant Outcomes in HIV-Infected Recipients A-112

Tracy Sparkes, PharmD, University of Maryland School of Pharmacy

Unique features of effector to memory transition render CD4+ T cells permissive for latent HIV infection B-101

Robert Siliciano, MD, PhD, Johns Hopkins University

Towards Achieving a State of Reversible HIV-1 Latency in Primary Monocyte-Derived Macrophages (MDM) by M1 Polarization B-102

Guido Poli, MD, Vita-Salute San Raffaele University

Genome-directed antiviral endonuclease therapy: promise and perils B-103

Keith Jerome, MD, PhD, University of Washington Lab Medicine

HIV Cure Research: a status report B-104

David Margolis, MD, University of North Carolina at Chapel Hill

Post Treatment Control: what predicts long-term HIV remission? B-105

John Frater, MD, PhD, University of Oxford

Characterizing the basis for the broad and potent HIV-specific neutralizing antibody response of infants B-106

Julie Overbaugh, PhD, Fred Hutchinson Cancer Research Center

Distinct mechanisms of hormonal control of HIV latency in T-cells and microglial cells B-107

Jonathan Karn, PhD, Case Western Reserve University

Specific HIV integration sites are linked to clonal expansion and persistence of infected cells B-108

Stephen H. Hughes, PhD, National Cancer Institute

HIV Latency and Perinatal Infection B-109

Deborah Persaud, MD, Johns Hopkins Children's Center

The HIV-1 antisense transcript AST promotes latency by recruiting PRC2 to the 5'LTR B-110

Romerio, PhD, Institute of Human Virology

Sulfotyrosine-Mediated V2-V3 Interaction Stabilizes the HIV-1 Envelope Trimer Facilitating Immune Evasion B-111

Paolo Lusso, MD, PhD, National Institute of Allergy and Infectious Diseases

Vaccines and Mechanisms of Host Defense C-101

Mark K. Slifka, PhD, Oregon National Primate Research Center at Oregon Health & Science University

Dissecting HIV-1 Transmission: Understanding Transmitted Founder Virus Biology C-102

Beatrice Hahn, MD, Perelman School of Medicine, University of Pennsylvania

Genetic Diversity of HIV Reveals the Epidemiological Role of High Risk Groups in Nigeria C-103

Man Charurat, PhD, Institute of Human Virology

A Tumor-Targeting Delivery Platform for p53 Therapy: Translation and Clinical Applications C-104

Esther H. Chang, PhD, Georgetown University

Insulin and IGFBP-3 Associated with Lung Cancer Susceptibility In Current Smokers C-105

Gloria Yuen Fun Ho, PhD, Albert Einstein College of Medicine

The Botswana Combination Prevention Project (BCPP): Addressing the UN 90-90-90 Targets for 2020 C-106

Myron Essex, DVM, PhD, T.H. Chan School of Public Health, Harvard University

Stigma and Depression Among Newly Diagnosed HIV Infected MSM in China C-107

Sten Vermund, MD, PhD, Institute for Global Health, Vanderbilt University Medical Center

Recent Cohort Data Suggest Revising US Cervical Cancer Screening Practices in HIV+ Women C-108

Howard Strickler, MD, Albert Einstein College of Medicine

HPV Associated Cervical Cancer in HIV negative African Women C-109

Clement Adebamowo, BM, ChB, ScD, FWACS, FACS, Institute of Human Virology

Human T lymphotropic virus types 1 and 2 (HTLV-1 and -2) and hepatitis C virus (HCV) epidemiology: lessons from studies of blood donors C-110

Edward L. Murphy Jr, MD, MPH, University of California, San Francisco

Progress toward poliomyelitis eradication - Nigeria, January 2014–July 2015 C-111

John Vertefeuille, PhD, Centers for Disease Control and Prevention

HIV-1 neutralizing antibodies induced by native-like envelope trimers D-101

Rogier Sanders, PhD, Weill Cornell Medical College

Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity D-102

Kwinten Sliepen MSc, University of Amsterdam

Studies on native-like SOSIP.664 trimers and other forms of Env D-103

John Moore, PhD, Weill Cornell Medical College

Molecular-level analysis of Env: What's on native trimers and how can we reproduce it in a vaccine? D-104

Heather Desaire, PhD, University of Kansas

Integrin a4b7 expression increases HIV susceptibility in activated cervical CD4+ T cells via an HIV attachment-in dependent mechanism D-105

Theresa L. Chang PhD, Rutgers University

Cellular Immune correlates Analysis of an HIV-1 Pre-exposure Prophylaxis Trial D-106

Douglas Nixon, MD, PhD, George Washington University

Vaccination establishes CXCR5+PD1+CD4+ peripheral blood germinal center T follicular helper cell relatives in humans D-107

Antje Heit, MD, PhD, Fred Hutchinson Cancer Research Center

Special Lecture: Human Antibodies to HIV-1 D-108

Michel Nussenzweig, MD, PhD, The Rockefeller University

Special Lecture: Fc Effector functions in the anti-viral response D-109

Jeffrey Ravetch, MD, PhD, The Rockefeller University

Reinhard Kurth Memorial Lecture: Zoonotic Origin of Some Common Human Cancers and Multiple Sclerosis? E-101

Harald zur Hausen, MD, Nobel Laureate, German Cancer Research Center in the Helmholtz Association

Ending the HIV/AIDS Pandemic: The Convergence of Treatment and Prevention E-102

Anthony Fauci, MD, National Institute of Allergy and Infectious Diseases

The Pathway to HIV Vaccine Development E-103

Barton Haynes, MD, Duke Human Vaccine Institute

Can non neutralizing antibodies be the basis for an effective HIV vaccine? Can we determine if RV 144 is “real or Memorex”? E-104

Larry Corey, MD, Fred Hutchinson Cancer Research Center

Antibodies Against Ebola Virus: Results of the Viral Hemorrhagic Fever Immunotherapeutic Consortium E-105

Erica Ollmann Saphire, PhD, The Scripps Research Institute

Establishment of a Clinical Research Program in the Setting of the Ebola Outbreak in West Africa E-106

Cliff Lane, MD, National Institute of Allergy and Infectious Diseases

Advancing Global Health: Lessons from the response to the HIV epidemic E-107

Salim Abdool Karim, PhD, Director, Centre for the AIDS Programme of Research in South Africa (CAPRISA)

Pharmacologic inhibition of the HIV-1 vif:apobec axis F-101

Mario Stevenson, PhD, University of Miami

HIV-1 matrix protein p17 promotes lymphangiogenesis by autophagy-mediated unconventional proteins secretion F-102

Alfredo Garzino-Demo, PhD, Institute of Human Virology

A conformational switch that turns on the B cell growth-promoting activity of the HIV-1 matrix protein p17 F-103

Wuyuan Lu, PhD, Institute of Human Virology

Hepatitis virus associated liver cancer: pathogenesis and immunotherapeutic strategies F-104

Luigi Buonaguro, MD, National Cancer Institute, “Fondazione Pascale”

Site-Specific Metastasis Revisited F-105

Isaac Witz, MD, PhD, Tel Aviv University

Transition State Gp120 Structures as HIV Vaccines F-106

Anthony DeVico, PhD, Institute of Human Virology

Adjuvant dependant RAS activation and mucosal envelope antibody to V2 correlate with reduced risk of Sivmac251 acquisition F-107

Genoveffa Franchini, National Cancer Institute, Bethesda

The role of a dual pre- and post- entry innate and adaptive immune mechanism in protection against HIV-1 infection F-108

Thomas Lehner, CBE, MD, Kings College London

Antigenicity of the Human Immunodeficiency Virus Envelope on Virions in Solution by Fluorescence Correlation Spectroscopy F-109

Krishanu Ray, PhD, University of Maryland School of Medicine

Special Lecture: The T cell receptor is a mechanosensor G-101

Ellis L. Reinherz, MD, Dana-Farber Cancer Institute

Modulating Env conformation: a new approach to eliminate HIV-1-infected cells G-102

Andrés Finzi, PhD, University of Montreal

Use of bnAbs and bnAb-based bispecific antibodies to target HIV- expressing cells in vivo G-103

Richard Koup, MD, Vaccine Research Center, National Institute of Allergy and Infectious Diseases

Breaking the species barrier: IgG subclasses in man and macaques G-104

Margaret Ackerman, PhD, Thayer School of Engineering at Dartmouth College

Defining protective antibody profiles against HIV utilizing systems serology G-105

Galit Alter, PhD, Harvard Medical School, Ragon Institute of MGH, MIT and Harvard

The pro- and anti-inflammatory effector functions of IgG G-106

Falk Nimmerjahn, PhD, Lehrstuhl Genetik, Friedrich-Alexander Universität Erlangen- Nürnberg

Enzymatic manipulation of antibody Fc-mediated effector functions G-107

Eric Sundberg, PhD, Institute of Human Virology

Some HIV-1 virions are more equal than others: Mosaics of Envs on individual HIV virions as evaluated with flow virometry G-108

Leonid Margolis, National Institute of Child Health and Development

TBK1/IKKε, the non-canonical IκB kinases, promote survival and proliferation of HTLV-1-transformed T cells by maintaining Stat3 activity G-109

Hua Cheng, PhD, Institute of Human Virology

Live attenuated rubella vectors stably express SIV Gag and HIV Env proteins in a highly immunogenic vaccine platform G-110

Ira Berkower MD, PhD, Lab of Immunoregulation, FDA

DNA prime/subunit boost using SIVE660 based rhFLSC yields 75% efficacy against cross clade SIVmac251 intrarectal challenge G-111

Kenneth Bagley, PhD, Profectus Biosciences

Does the gut microbiome affect mucosal immune activation and intrarectal susceptibility to SHIV acquisition in naive rhesus macaques? P-A1

Yongjun Sui, PhD, National Cancer Institute, National Institute of health

Towards curtailing HIV latency by combinatorial unblocking viral transcription P-A2

Suresh K Arya, PhD, National Institutes of Health

Identification of proximal biomarkers of PKC agonist activity in HIV-1 latently infected cells P-A3

Sai Vikram Vemula, PhD, Merck

Novel CD4-Based Bi-specific Chimeric Antigen Receptors: Toward a Functional Cure of HIV Infection P-A4

Sara Bolivar-Wagers, BS, NIAID, National Institutes of Health

Prolactinoma in A Transgender Male-To-Female HIV Positive Adult-A Rare Occurrence & A Therapeutic Dilemma P-B1

Waqas Jehangir, MBBS, MD, Raritan Bay Medical Center, Perth Amboy, NJ

Performance of WHO immunological response to predict virological failure in patients with severe versus moderate immunosuppression at antiretroviral therapy initiation P-B2

Martin Herbas Ekat, MD, Ambulatory Treatment Center of Brazzaville

Evaluation of an In-house Molecular HIV-1 Test to Assess Mother-to-Child HIV-1 Transmission in Angola (the APEHC Cohort) P-B3

Francisco N Martin, Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon, Portugal

Predictors Of Sustained Viral Response To 4-6 Week Duration Therapy With Ledipasvir + Sofosbuvir + Gs-9451 +/− Gs-9669 In Early And Advanced Fibrosis (Nih-Ihv Synergy Trial) P-B4

Sarah Kattakuzhy, MD, IHV

Examining the association of circumcision, sexual behavior and HIV status among men aged 15-59 in Uganda P-B5

Mian B. Hossain, PhD, Morgan State University

Development of a Potency Assay for Full Length Single Chain, a subunit vaccine for HIV P-B6

Timothy Fouts, PhD, Profectus BioSciences

Balance of Cellular and Humoral Immunity Determines the Level of Protection by HIV Vaccines in Rhesus Macaque Models of HIV Infection P-B7

Timothy Fouts, PhD, Profectus BioSciences

Software dependent differences in HIV-1 drug resistance determination P-B8

Boyka Baltadjieva, MD, ACL Central Lab at Rosemont, IL

TSCQ Study: A randomized, open-label controlled trial of daily trimethoprim- sulfamethoxazole or weekly chloroquine among adults on antiretroviral therapy in Malawi P-B9

Matthew B. Laurens, MD, MPH, Center for Vaccine Development, University of Maryland School of Medicine

Egyptian Healthcare Workers and Hepatitis C Virus Vaccines P-B10

Sayed F. Abdelwahab, PhD, Taif University College of Pharmacy

Retreatment of HCV GT-1 in Patients Who Failed Previous Short Course Combination DAA Therapy With 12 Weeks of LDV/SOF is Highly Effective P-B11

Eleanor M. P. Wilson, MD, MHS, Institute of Human Virology, University of Maryland School of Medicine

Comparison Of Hpv Genotyping Using Roche Linear Array With Spf10- Deia Lipa 25 Version 1 In Nigerian Women Presenting For Cervical Cancer Screening P-B12

Oluranti A. Famooto, BSc, Institute of Human Virology, Abuja, Nigeria

Comparison of two HPV detection and genotyping systems in a Nigerian screening population P-B13

Clement Adebamowo, BMChB, ScD, Institute of Human Virology, Greenbaum Cancer Center; Division of Cancer Epidemiology, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore

Methylation as a triage marker in a hHPV+ population in Nigeria P-B14

Clement Adebamowo, BMChB, ScD, Institute of Human Virology, Greenbaum Cancer Center and Division of Cancer Epidemiology, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore

The Burden of Human Papilloma Virus Associated Cancers in Nigeria 2012–2014 P-B15

Elima E. Jedy-Agba, MBBCh, MSc, Institute of Human Virology Nigeria

The Burden of Human Papilloma Virus Associated Cancers in Nigeria 2012–2014 P-B16

Clement Adebamowo, BMChB, ScD, Institute of Human Virology, Greenbaum Cancer Center; Division of Cancer Epidemiology, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore. Nigerian National System of Cancer Registries Coordinating Center, Abuja, Nigeria

Persistent Human Papillomavirus Infection in a Cohort of Nigerian Women P-B17

Eileen O. Dareng, MD, MPH, Department of Strategic Information, Research and Training, Institute of Human Virology, Abuja, Nigeria Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom

Prevalence of anal high-risk human papillomavirus infections among HIV- positive and HIV-negative men who have sex with men (MSM) in Nigeria P-B18

Rebecca G. Nowak, PhD, Institute of Human Virology, University of Maryland School of Medicine

Colorectal Neoplastic Lesions In HIV-Infected Patients Compared To Non- HIV-Infected Patients P-B19

Rebecca G. Nowak, PhD, Institute of Human Virology, University of Maryland School of Medicine, Department of Epidemiology and Public Health, Univeristy of Maryland School of Medicine

Evaluation of the feasibility of incorporating HPV DNA-based cervical cancer screening into routine antenatal care in Nigeria: A qualitative study P-B20

Temitope Filade, BNSc, MSc, Institute of Human Virology Nigeria

Validation of HPV genotyping at the African Collaborative Centre of Microbiome and Genomics Research, Institute of Human Virology Nigeria P-B21

Ayotunde Famooto, MSc, African Collaborative Centre of Microbiome and Genomics Research, Institute of Human Virology, Nigeria

Recurrence of Cervical Intraepithelial Lesions after Thermo-coagulation in HIV-positive and HIV-negative Nigerian Women P-B22

Emmanuel A. Oga, MD, MPH, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA

Prevalence of Ebola viral entry resistance in a diverse population P-B23

Praveen F. Cherukuri, PhD, Inova Translational Medicine Institute

Factors Associated With Attrition in a Prospective Cohort Study in Nigeria P-B24

Eileen O. Dareng, MD, MPH, Center for Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom, Institute of Human Virology, Nigeria

Influence of Spirituality and Modesty on Acceptance of Self Sampling for Cervical Cancer Screening P-B25

Eileen O. Dareng, MD, MPH, Center for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom, Institute of Human Virology, Nigeria

Changes in Plasma BLyS Levels in Patients with HCV Mixed Cryoglobulinemic Vasculitis during Treatment with Rituximab P-B26

Emily Comstock, RN, BSN, BA, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201

Targeting the binding interface on a shared receptor subunit of a cytokine family enables the inhibition of multiple member-cytokines with selectable target spectrum P-B27

Yutaka Tagaya, MD, PhD, Institute of Human Virology, Unversity of Maryland School of Medicine

Dichotomous Effects of Immune based (Interferon-alpha) and Non-immune based (direct acting antiviral) Therapies on Lipid Biosynthesis P-B28

Lydia Tang, MBChB, Institute of Human Virology, University of Maryland School of Medicine, Division of Infectious Diseases

Barriers to Cervical Cancer Screening Among Nigerian Women P-B29

Elima E. Jedy-Agba, MBBCh, MSc, Institute of Human Virology Nigeria, Department of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, United Kingdom

Association Between HIV and Persistent HPV Infections Among Nigerian P-B30

Women Sally N. Adebamowo, MD, MSc, ScD, IHVN, NHGRI

Cohort Profile: African Collaborative Center for Microbiome And Genomics Research (ACCME) Study P-B31

Sally N. Adebamowo, MD, MSc, ScD, IHVN, NHGRI

cGMP production, characterization, and formulation of IHV01 drug product, the Full Length Single Chain gp120-CD4 (FLSC) chimera formulated in Aluminum Phosphate P-B32

Ilia Prado, MS, MBA, Profectus BioSciences

HPV Persistence and Age-Specific Type Distribution Among Nigerian Women P-B33

Sally N. Adebamowo, MD, MSc, ScD, IHVN, NHGRI

Postural tachycardia syndrome (POTS) after Varicella Zoster virus infection (chicken pox): a case report P-B34

Pranith H. Kumar, MBBS, MD, University Of Maryland School of Medicine

Design of a broadly neutralizing human rhinovirus antigen P-B35

Wiggins, T; Lee, W-M; Bushnell, RV; Tobin, JK; Turner, RB; Nara, PN; Tobin, GJ

Full Length Single Chain, A Novel gp120-CD4 Fusion HIV Subunit Vaccine, Does Not Cause a Deleterious Autoimmune CD4 Response in Cynomolgus Macaques P-C1

Jennifer A. Schwartz, PhD, Profectus Biosciences

T-cell Based Lentiviral Vaccines P-C2

Shannon R. Roff, MS, DVM, University of Florida College of Veterinary Medicine

Targeting the Epitopes in the C1-C2 Region of HIV-1 gp120 for Effective Fc-mediated Effector Function P-C3

Neelakshi Gohain, PhD, University of Maryland

Targeted Sequencing of Broadly Neutralizing Anti-HIV Envelope Antibodies Directly from Plasma P-C4

Mohammad M. Sajadi, Institute of Human Virology

Selection and characterization of neutralizing nanobodies from dromedaries immunized with soluble trimeric HIV-1 Env SOSIP proteins P-D1

Ursula Dietrich, PhD, Georg-Speyer-Haus

Microscopic Detection and Localization Of HIV Gp120 Epitope Exposures On Cell-Bound Virions P-D2

Meron Mengistu, PhD, Institute of Human Virology of the University of Maryland School of Medicine

Structural Determinants for the Selective Anti-HIV-1 Activity of the All-beta Alternative Conformer of XCL1 P-D3

Christina Guzzo, PhD, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Disease (NIAID), NIH, Bethesda, MD

Tyrosine-Sulfated Peptides from the gp120 V2 Domain Block HIV-1 Entry through CCR5 Mimicry P-D4

Qingbo Liu, PhD, National Institute of Allergy and Infectious Diseases, NIH

Two Conserved Tyrosines in the HIV-1 Envelope V2 Loop Play a Critical Role in gp120/gp41 Association P-D5

Peng Zhang, PhD, NIAID, NIH

Effects of influenza vaccination on lymphoid architecture in HIV+ patients on combination antiretroviral therapy (cART) P-D6

Eirini Moysi, PhD, Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL and Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD

Structural mimicry of the antigen binding modes of rhesus macaque and human anti-gp120 V3 antibodies P-D7

Ruimin Pan, PhD, New York University School of Medicine

Targeting of the catalytic site of host mTOR controls HIV in vivo P-D8

Alonso Heredia, PhD, IHV

A Novel Small Molecule Inhibitor of HIV-1 Entry P-D9

Alonso Heredia, PhD, IHV

Differential Induction of Anti-V3 Crown Antibodies with Cradle and Ladle-Binding Modes in Response to HIV-1 Envelope Vaccination P-D10

Preetha Balasubramanian, MS, NYU Sackler institute

Effect of HIV-1 matrix protein p17 on natural killer cell mediated antibody- dependent cellular cytotoxicity P-D11

Virginia Carroll, PhD, Institute of Human Virology, University of Maryland School of Medicine

Differential Sensitivity of HIV-1 Isolates to Inhibition by Mannose-Binding Lectins Reveals the Heterogeneity of the Virus Envelope Glycosylation P-D12

Muzafar JAN Peer, New York University school of medicine New York, USA

Resistance to N-peptide fusion inhibitors: implications for HIV entry P-D13

Paul W. Keller, PhD, Food and Drug Administration

Modulation of SIV and HIV DNA Vaccine Immunity by Fas-FasL Signaling By Jiabin Yan, Juan Carlos Zapata, Charles David Pauza and Maria S. Salvato (presenting) P-D14

Maria S. Salvato, PhD, University of Maryland School of Medicine, Institute of Human Virology, Baltimore, Maryland

Peripheral Blood Lymphocyte HIV DNA Levels Correlate with HIV Associated Neurocognitive Disorders P-D15

Jibreel A. Jumare, MBBS, University of Maryland

CD44 and RUNX2: Possible Targets for Prostate Cancer in Bone Microenvironment P-E1

Aditi Gupta, PhD, University of Maryland, Baltimore, Maryland

An Hsc70-binding peptide derived from SV40 Large T antigen is a potent inhibitor of polyoma virus DNA replication P-E2

Neera Sriskandarajah, MSc, Molecular Virology Research Unit, Institut de recherches cliniques de Montréal (IRCM) Division of Experimental Medicine, McGill University

Development of a new humanized mouse model to study anti-HTLV-1 immunity P-E3

Juan C. Zapata, PhD, Institute of Human Virology, University of Maryland

HLBT-001- A flavonoid from Tillandsia recurvata shows potent anticancer activity against Aids-Defining and Non-Aids defining cancers P-E4

Ngeh J. Toyang, PhD, IHV, University of Maryland School of medicine/Educational & Scientific LLC

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.